If you are looking for reliable dividend stocks, you'll want to examine T. Rowe Price, Scotiabank, and Agree Realty right now.A consistent stream of passive income is likely what you'll be looking for if you are retired. But you'll want to make sure that the dividends you're collecting are going to keep going for decades, which is exactly why you should take a look at T. Rowe Price (TROW 0.43%), Bank of Nova Scotia (BNS 1.00%), and Agree Realty (ADC 0.56%) right now.Annuity-like income at T. Rowe PriceMost ...

Group 1 - The article mentions that Parkev Tatevosian, CFA, has no position in any of the stocks mentioned [1] - The Motley Fool recommends Alibaba Group, indicating a positive outlook on the company [1] - Parkev Tatevosian is affiliated with The Motley Fool and may receive compensation for promoting its services, which could influence his opinions [1]

Blue-chip dividend stocks are adding fuel to the market rally.The best dividend stocks can have a tough time keeping pace with a rip-roaring, growth-fueled bull market. After all, the whole idea of a dividend is to pass along a portion of profits directly to shareholders instead of reinvesting them in the business.Naturally, dividend-paying companies tend to be lower growth. But Walmart (WMT 1.51%), Target (TGT -0.59%), Procter & Gamble (PG 0.62%), and Emerson Electric (EMR) have not only paid and raised th ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Walmart. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Salesforce was one of the first big tech companies in 2024 to announce a dividend.It seems like more tech companies are starting to pay dividends as a new way to excite investors about their stock. Salesforce (CRM -1.15%) was one of the first to participate in this trend, but the question is, is it a good idea? After all, there's still a lot of growth to be had.However, investors should know some facts about dividends. While this may not be great news for Salesforce as a business, it's excellent news for Sa ...

Just because the S&P 500 hit a new all-time high doesn't mean all stocks are expensive.The S&P 500 just reached a new all-time high and the Dow Jones Industrial Average broke the 40,000 level for the first time ever. However, in this video, Fool.com contributors Matt Frankel, CFP®, and Tyler Crowe talk about two stocks they recently bought that could be excellent long-term opportunities.*Stock prices used were the morning prices of May 17, 2024. The video was published on May 18, 2024. ...

This fast-growing chipmaker has a lot of advantages. But there is one big risk investors should be aware of.If you want to bet on generative artificial intelligence (AI), there is still no better pick than Nvidia (NVDA 0.64%). The company dominates the market for cutting-edge AI data center chips. And unsurprisingly, shares have risen by a whopping 206% over the last 12 months alone. But can the bull run continue? Let's look at three reasons to continue buying Nvidia stock and one reason why it might be tim ...

This pharma giant just made a smart strategic acquisition.There are plenty of reasons to buy a leading biopharma business like AbbVie (ABBV -0.99%), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it could now become a prominent psychiatric-drug company.Though the area isn't traditionally in AbbVie's wheelhouse, there's reason to believe that its latest bet will turn out well for investors. Here's why.This new segment could be incredibly valuableOn May ...

Group 1: Market Overview - The stock market is experiencing significant growth, with the Nasdaq and S&P 500 reaching new record highs, indicating a bull market phase that is expected to last longer than bear markets [1][2] - Historical data shows that the average bull market lasts nearly nine years, while bear markets last approximately 1.4 years, suggesting ample time for investors to benefit from current market conditions [2] Group 2: Biotech Industry Potential - The biotech industry presents numerous investment opportunities, particularly for companies that have recently received product approvals, signaling strong growth potential [3] - Companies with solid long-term prospects are likely to provide returns that extend beyond the current bull market [2] Group 3: CRISPR Therapeutics - CRISPR Therapeutics has received regulatory approval for Casgevy, a treatment for sickle cell disease and beta thalassemia, marking the first approval of a CRISPR-based treatment [4][5] - The company has over 25 authorized treatment centers ready to launch Casgevy, with multiple patients already in the treatment process, indicating strong initial demand [5] - CRISPR is also developing a lighter conditioning treatment and in vivo gene editing of stem cells, which could broaden the application of its technology and enhance patient uptake [6] - The stock is currently trading lower than in previous years, presenting a buying opportunity for growth investors as the Casgevy launch progresses [7] Group 4: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in tumor infiltrating lymphocyte (TIL) treatments and has received approval for Amtagvi, its first commercialized TIL product for advanced melanoma [8][9] - The company reports that over 100 patients have enrolled for Amtagvi since its approval, with plans to establish 50 authorized treatment centers by the end of the month and over 70 by year-end [10] - Amtagvi has received reimbursement approvals from payers covering over 200 million people, enhancing accessibility for patients in need [11] - Iovance is also leveraging its technology across its pipeline, indicating potential for additional growth drivers in the future [12]

The company is striking new partnerships to extend its AI reach.International Business Machines (IBM 2.09%) has found its footing in the AI market by focusing on enterprise customers with complex requirements. The company's watsonx platform caters to companies and organizations that need to train, tune, and deploy AI applications while minding regulatory, legal, and other concerns.This strategy is going well for IBM so far. The company has a book of business related to watsonx and generative AI that tops $1 ...